ライフサイエンスコーパス: neutral endopeptidase

1 muscle is due to interaction with the enzyme neutral endopeptidase.

2 rphin A was prevented by aminopeptidases and neutral endopeptidase.

3 he first evidence that keratinocytes produce neutral endopeptidase.

4 idase A and B, chymotrypsin, subtilisin, and neutral endopeptidase.

5 oup, comprise the M13 subfamily of mammalian neutral endopeptidases.

6 shares homology to members of the family of neutral endopeptidases.

7 e molecules that simultaneously inhibit both neutral endopeptidase 24.1 (NEP) and ACE.

8 The cell surface zinc metalloproteinase CD10/neutral endopeptidase 24.11 ([NEP] neprilysin) functions

9 eptidases, namely aminopeptidase N (APN) and neutral endopeptidase 24.11 (NEP 24.11).

10 s, angiotensin I-converting enzyme (ACE) and neutral endopeptidase 24.11 (NEP) are the major kininase

11 plays high amino acid sequence identity with neutral endopeptidase 24.11 (NEP) especially at the cata

12 ration of action in vivo, the dual ECE-1 and neutral endopeptidase 24.11 (NEP) inhibitor, CGS 26303,

13 zofused macrocyclic lactams were designed as neutral endopeptidase 24.11 (NEP) inhibitors.

14 Neutral endopeptidase 24.11 (NEP) is a cell surface pept

15 Neutral endopeptidase 24.11 (NEP) is a cell-surface enzy

16 Neutral endopeptidase 24.11 (NEP) is a cell-surface pept

17 Neutral endopeptidase 24.11 (NEP) is a metalloprotease t

18 CD10/neutral endopeptidase 24.11 (NEP) regulates peptidemedia

19 n the crystal structure of the ectodomain of neutral endopeptidase 24.11 (NEP).

20 Neutral endopeptidase 24.11 (NEP, CD10) is a cell-surfac

21 ty and a small, but significant, increase in neutral endopeptidase 24.11 activity in the cheek pouch,

22 Because the enzyme neutral endopeptidase 24.11 is an important kininase in

23 Kell has closest homology with neutral endopeptidase 24.11, endothelin converting enzym

24 thway is under the control of three enzymes: neutral endopeptidases 24.11 (neprilysin) and 24.15 and

25 Adjacent skin had a median neutral endopeptidase activity 4.34 x higher (p<0.001) t

26 This elevated neutral endopeptidase activity in the skin and chronic u

27 The median neutral endopeptidase activity of proximal skin was 2.90

28 The median neutral endopeptidase activity of the ulcer margin was 1

29 The neutral endopeptidase activity was approximately 7-fold

30 Neutral endopeptidase activity was measured using a fluo

31 scular drug that simultaneously inhibit both neutral endopeptidase and angiotensin-converting enzyme

32 ANP and fsANP are preferentially degraded by neutral endopeptidase and serine peptidases, respectivel

33 We investigated whether neutral endopeptidase could inhibit angiogenesis in vivo

34 The cell surface enzyme, neutral endopeptidase, degrades substance P, thereby reg

35 in metabolism is dependent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and amin

36 lts from this investigation demonstrate that neutral endopeptidase (EC 3.4.24.11) is one of the major

37 terized using a monoclonal antibody to human neutral endopeptidase, EC 3.4.24.11.

38 carotid body is structurally similar to the neutral endopeptidase, EC 3.4.24.11.

39 We hypothesized that neutral endopeptidase enzymatic activity is increased in

40 Neutral endopeptidase enzymatic bioactivity was demonstr

41 We compared cutaneous neutral endopeptidase expression and enzymatic activity

42 he objectives of this study were to evaluate neutral endopeptidase expression in wounded and unwounde

43 d on Xp22.1, is homologous to members of the neutral endopeptidase family.

44 c injury that treatment with GLP-1(28-36), a neutral endopeptidase-generated (NEP-generated) metaboli

45 The distribution of neutral endopeptidase in normal skin and wounded human s

46 vascular endothelial cells demonstrated that neutral endopeptidase inhibition significantly enhanced

47 Three strategies were tested: inhibition of neutral endopeptidase, inhibition of aldose reductase pl

48 se severity when given in combination with a neutral endopeptidase inhibitor (enhances endogenous nat

49 -135 and Gly-136, which was inhibited by the neutral endopeptidase inhibitor CGS24592 and heparin.

50 Through single coinjection of the neutral endopeptidase inhibitor phosphoramidon (PA), we

51 ibitor captopril, to -6.33 +/- 0.19 with the neutral endopeptidase inhibitor phosphoramidon and to -7

52 eletal muscle, we examined the effect of the neutral endopeptidase inhibitor phosphoramidon on the bi

53 ramiprilat (10(-4) mol/L, -21+/-2%), and the neutral endopeptidase inhibitor thiorphan (10(-4) mol/L,

54 (n = 10), phosphoramidon (a combined ECE and neutral endopeptidase inhibitor) and BQ-123 (an ETA rece

55 2), respectively, and thiorphan (a selective neutral endopeptidase inhibitor) reduced FBF by 15 +/- 5

56 he transcriptome, and identified thiorphan-a neutral endopeptidase inhibitor-as a lead candidate.

57 n=87) versus the vasopeptidase (dual ACE and neutral endopeptidase) inhibitor omapatrilat 80 mg daily

58 Clinical studies of neutral endopeptidase inhibitors and angiotensin II rece

59 Neutral endopeptidase is a cell surface enzyme that degr

60 the matrix metalloproteinase (MMP) family of neutral endopeptidases, is expressed in the skeleton dur

61 Neutral endopeptidase may terminate the proinflammatory

62 Neutral endopeptidase mRNA was detected in normal skin a

63 es like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptidase (NEP) 24.11 severely compromises i

64 y was to establish the effect of oleacein on neutral endopeptidase (NEP) activity and other functions

65 both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) activity in vitro were obser

66 fections and HOXC6 overexpression identified neutral endopeptidase (NEP) and insulin-like growth fact

67 gest that insulin-degrading enzyme (IDE) and neutral endopeptidase (NEP) are involved in the extracel

68 s of angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) both in vitro and in vivo.

69 Neutral endopeptidase (NEP) degrades vasoactive peptides

70 f the natriuretic peptide (NP) receptors and neutral endopeptidase (NEP) in mediating and modulating

71 The cell-surface enzyme neutral endopeptidase (NEP) inactivates both peptides.

72 e herein our efforts to identify a selective neutral endopeptidase (NEP) inhibitor as a potential tre

73 Neutral endopeptidase (NEP) is a cell surface enzyme fou

74 Neutral endopeptidase (NEP) is a cell-surface enzyme tha

75 Neutral endopeptidase (NEP) is a genetically distinct me

76 Neutral endopeptidase (NEP) is expressed on normal prost

77 as the expression of the SP-degrading enzyme neutral endopeptidase (NEP) is increased, compared to co

78 the angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) may produce greater benefits

79 ical, and modeling approaches, we identified neutral endopeptidase (NEP) that is up-regulated in huma

80 Neutral endopeptidase (NEP) uses SP as a substrate to pr

81 ndrogen-sensitive LNCaP cells, which express neutral endopeptidase (NEP), but not in androgen-indepen

82 nt vasoconstrictor into its active form, and neutral endopeptidase (NEP), which is involved in termin

83 ors indicated that the previously identified neutral endopeptidase (NEP)-like activity is the major p

84 nstrated substrate preference for Ang I, was neutral endopeptidase (NEP)-like.

85 and absence of long-term oral inhibition of neutral endopeptidase (NEP).

86 kephalin, the natural substrate of the human neutral endopeptidase (NEP).

87 both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).

88 nhibitors of the two zinc metallopeptidases, neutral endopeptidase (NEP, EC 3.4.24.11) and angiotensi

89 Neutral endopeptidase (NEP; CALLA, CD10, EC 3.4.24.11) i

90 ed plasma half-life due to its resistance to neutral-endopeptidase (NEP) digestion.

91 ich blocks angiotensin converting enzyme and neutral endopeptidase, on these endpoints.

92 common acute lymphoblastic leukemia antigen, neutral endopeptidase, or enkephalinase, can be used as

93 dipeptidyl carboxypeptidase (captopril), and neutral endopeptidase (phosphoramidon) dramatically incr

94 By 28 d post wounding neutral endopeptidase staining again was detected only i

95 me required for kidney membranes or purified neutral endopeptidase to abolish ANP-dependent activatio

96 Neutral endopeptidase was localized by immunohistochemis

97 Staining for neutral endopeptidase was noted in the wound bed 6 h aft

98 Neutral endopeptidase was strikingly localized in normal

99 otein levels of the enzyme that degrades SP, neutral endopeptidase, were increased.

100 Incubation with neutral endopeptidase, which degrades bombesin, or bombe

101 eptidase inhibitors inhibit ACE activity and neutral endopeptidase, which degrades natriuretic peptid

102 bits angiotensin-converting enzyme (ACE) and neutral endopeptidase, which degrades vasodilatory facto

103 at released opioids are primarily cleaved by neutral endopeptidase, with a lesser involvement of amin